4

Back to all posts

Equine Amnio Solutions Signs Exclusive Agreement For Distribution Of RenoVō®, A Next-Generation Equine Regenerative Product
Renovo Horse Background

ARGYLE, TEXAS, March 25, 2021 — Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation equine regenerative products, announced today that Covetrus, a global leader in animal health technology and services, will be the exclusive distributor of the RenoVō® equine allograft throughout the United States.

RenoVō® is an acellular, cryopreserved liquid allograft derived from equine amniotic tissues intended for equine use. Amniotic birth tissues are rich sources of bioactive factors involved in tissue regeneration with reported anti-inflammatory, anti-bacterial and anti-fibrotic properties.

RenoVō® is uniquely processed through a proprietary process to optimize protein retention and stability. The product is supplied in volumes of 1.5 cc, 3.0 cc and 5.0 cc and is maintained frozen before use to preserve beneficial proteins which may not survive desiccation procedures common to industry. Compelling clinical evidence has established the product as a safe and efficacious option for the equine practitioner and RenoVō® continues to enjoy rapid adoption among veterinarians and owners as an alternative to autologous and other therapies.

EAS works closely with its product manufacturer, Equus Innovations (Phoenix, Arizona). Grant D. Senner, MD, DABRM and Equus Innovations’ Chief Executive Officer stated, “We are extremely excited to partner with Covetrus to expand the distribution and clinical use of RenoVō®. Our mission has always been to provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines. Covetrus is the ideal partner to help us establish RenoVō® as a new standard of care for the equine practitioner.”

About Equine Amnio Solutions

Equine Amnio Solutions, LLC (EAS) is the market leader in the distribution of next-generation regenerative veterinary products, including RenoVō®. EAS works closely with its product manufacturer, Equus Innovations (Phoenix, Arizona). Our mission is to provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines.

RenoVō® is a Registered Trademark of Equine Amnio Solutions, LLC.

You may want to read these articles

RenoVō® CASE STUDY: Puncture Wound

RenoVō® CASE STUDY: Puncture Wound

Case presentation - June 9, 2022: A three-year-old Quarter Horse filly backed into the catch for the stall door and punctured herself, creating a large, deep wound on her left thigh. The wound was sutured with internal and external stiches at clinic, however the...

RenoVō® CASE STUDY: Superficial Digital Flexor Tendon (RH)

RenoVō® CASE STUDY: Superficial Digital Flexor Tendon (RH)

Case presentation - June 9, 2016: A 9 year old Warmblood jumping horse presented with a superficial digital flexor tendon injury of the right hind leg. The horse was treated with stem cell injections. After 10 months of rest and rehabilitation, the horse slowly went...

RenoVō® CASE STUDY: Summer Sore

RenoVō® CASE STUDY: Summer Sore

Case presentation - June 17, 2022: A 19-year-old Red Horse presented to Topgun Veterinarian Service, Rock Hill, SC, with a large Summer Sore on the commissure of the right side of the mouth. The horse was treated orally with Ivermectin and topically with Ivermectin...